Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
FDA approves Astellas' gastric cancer therapy
The U.S. Food and Drug Administration approved Astellas' therapy to treat a type of gastric cancer, the health regulator's website showed on Friday.
FDA Greenlights Vyloy for Gastric Cancer, Egypt Achieves Malaria-Free Status
The FDA has approved Astellas' Vyloy to treat gastric cancer. Egypt has been certified malaria-free by WHO. A Tennessee court temporarily blocked parts of the state's abortion ban. Sanofi plans to sell stakes in Opella.
FDA Approves First-in-Class Drug for Gastric Cancer
Zolbetuximab — now with the brand name Vyloy — is a monoclonal antibody to treat patients with advanced gastric and gastroesophageal cancers.
Astellas nabs class-first FDA approval for CLDN18.2 gastric cancer med Vyloy
After a prior rejection, Astellas can head into the weekend celebrating a class-first FDA approval for its new gastric cancer med Vyloy. | Astellas' Vyloy won an FDA approval to treat gastric or gastroesophageal junction adenocarcinoma patients whose tumors are CLDN18.
FDA OKs Zolbetuximab for Gastric, Gastroesophageal Cancer
FDA also approved the Ventana CLDN18 (43-14A) RxDx Assay, from Ventana Medical Systems, Inc. and Roche Diagnostics, to identify claudin 18.2–positive tumors and thus patients who may be eligible to receive zolbetuximab.
VYLOY: Astellas’ gastric cancer therapy approved in US
Astellas Pharma today announced that the US Food and Drug Administration (FDA) has approved VYLOY (zolbetuximab-clzb) in combination with
Astellas Pharma’s VYLOY Gains FDA Approval for Cancer Treatment
Astellas Pharma (JP:4503) has released an update. Astellas Pharma has received FDA approval for VYLOY, a novel treatment targeting CLDN18.2 for
Astellas Pharma's Cancer Drug Vyloy Gets FDA Approval
Astellas Pharma's drug Vyloy was approved for treatment of advanced gastric and gastroesophageal junction cancer by the Food and Drug Administration. The pharmaceutical company said Friday the FDA approved the drug for use in combination with fluoropyrimidine-and-platinum-containing chemotherapy.
devdiscourse
1d
Health Headlines: FDA Greenlights Cancer Therapy, Leadership Shakeup at CVS, and Global Health Insights
The FDA approved Astellas' gastric cancer therapy. CVS Health CEO Karen Lynch steps down amid shareholder pressure, with ...
6d
on MSN
Clinical trials confirm zolbetuximab's efficacy in gastric cancer
In Germany, around 17,000 people are diagnosed with gastric cancer every year. The disease is one of the leading causes of ...
Tuko on MSN
2d
Nairobi man diagnosed with stage 3 gastric cancer seeks help to raise KSh 600k for treatment
Former Communication Authority of Kenya employee, Mathew Nyamlori who was diagnosed with stage 3 gastric cancer in 2023 seeks ...
technologynetworks
6d
Drug Extends Survival in Gastric Cancer Clinical Trial
In Germany, around 17,000 people are diagnosed with
gastric
cancer
every year. The disease is one of the leading causes of tumour-related deaths. This is due to late diagnosis and the rapid spread ...
3d
Conversion surgery for metastatic gastric cancer now viable, says expert at Prof S.M. Chandramohan oration
Conversion surgery is becoming a viable option for patients with metastatic gastric cancer who respond well to induction ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
United States
Astellas Pharma
Vyloy
Zolbetuximab
Feedback